Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio, Inc. (THRD) generated news primarily as a clinical-stage biopharmaceutical company focused on dermal, respiratory, and gastrointestinal inflammatory diseases driven by mast cells. Its disclosures describe a research and development strategy centered on novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that regulates mast cell function and survival. The company’s news flow highlighted progress and decisions around its lead KIT inhibitor programs and subsequent corporate actions.
Earlier news items focused on the clinical development of THB335, a titratable, oral small molecule inhibitor of KIT. Releases covered the design and progress of a Phase 1 single and multiple ascending dose trial in healthy volunteers, including safety, pharmacokinetics, and pharmacodynamic effects measured through reductions in serum tryptase, a biomarker of mast cell activation. Updates also addressed Phase 2 readiness activities in chronic spontaneous urticaria, including completion of clinical, toxicology, and manufacturing work to support a potential Phase 2 trial.
Financial and corporate updates formed another major category of news. Third Harmonic Bio reported quarterly and annual financial results, describing research and development spending trends, the shift away from its THB001 program, and what it characterized as a strong cash and cash equivalents position. The company also issued releases about participation in healthcare and investor conferences, where management discussed its development programs and strategic outlook.
Later news items document a significant strategic shift. Third Harmonic Bio announced a strategic review process to explore potential strategic transactions and business combinations, halted non-THB335 research activities, and implemented workforce reductions. Subsequent releases described the board’s approval of a Plan of Liquidation and Dissolution, stockholder approval of the plan, expected liquidation distributions to stockholders, and the initiation of a sale process for THB335 and related intellectual property.
For readers researching THRD, this news archive provides a record of Third Harmonic Bio’s clinical data disclosures, financial reporting, strategic reviews, and ultimately its decision to liquidate and dissolve, including the steps toward delisting and winding down operations.
Third Harmonic Bio (Nasdaq: THRD) has announced its Board of Directors' approval of a Plan of Liquidation and Dissolution, subject to stockholder approval at the Annual Meeting on June 5, 2025. The company plans to distribute remaining cash to stockholders and sell its assets, including the THB335 program.
The initial distribution is expected to be between $246.6 million and $255.4 million (approximately $5.13-$5.33 per share) in Q3 2025. The total distribution could reach between $246.6 million and $259.8 million ($5.13-$5.42 per share), not including potential proceeds from asset sales.
Following stockholder approval, the company intends to file a Certificate of Dissolution, delist from Nasdaq, resolve remaining liabilities, and convert assets to cash. The company will complete Phase 2 readiness activities for THB335 by mid-year to maximize potential value from the asset sale process.
Third Harmonic Bio (THRD) reported its Q4 and full year 2024 financial results, highlighting successful Phase 1 clinical trial results for THB335, their oral KIT inhibitor for chronic spontaneous urticaria (CSU). The company plans to initiate a 12-week Phase 2 study by mid-2025.
Financial highlights include a strong cash position of $285.1 million as of December 31, 2024, with projected cash reserves between $262-267 million by June 30, 2025. The company reported increased R&D expenses of $36.5 million for 2024 (up from $24.0 million in 2023) and G&A expenses of $22.4 million (up from $20.0 million). Net loss widened to $45.5 million in 2024 from $30.8 million in 2023.
In February 2025, THRD initiated a strategic alternatives process, halted non-THB335 research activities, and reduced workforce by 50% to maximize shareholder value.
Third Harmonic Bio (THRD) has announced positive Phase 1 clinical results for THB335, supporting advancement to Phase 2 trials in chronic spontaneous urticaria (CSU). The trial demonstrated that THB335, a KIT inhibitor, achieved dose-dependent reductions in serum tryptase ranging from 13% to 84%, with multiple dose levels showing potential clinical benefit.
The company reported the drug was generally safe and well-tolerated, with a 40-hour half-life enabling once-daily dosing. While some adverse events were observed, including hair color changes and blood count reductions, these were largely dose-dependent and resolved during follow-up.
THRD is initiating a strategic review process while preparing for Phase 2 trials, including a workforce reduction of 50%. The company maintains a strong financial position with approximately $285 million in cash as of December 2024, projecting $262-267 million by June 2025 after accounting for Phase 2 preparations and restructuring costs.
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Chris Murphy, Chief Financial and Business Officer, will engage in a fireside chat on December 4, 2024, at 9:35 a.m. The company, which focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide a live audio webcast accessible through their website's Investors & Media section. The replay will remain available for 90 days after the event.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, has announced its participation in two major investor conferences this November. Natalie Holles, CEO, will present at the Stifel 2024 Healthcare Conference on November 19 at 3:00 p.m. EST, while Chris Murphy, CFO, will speak at the Jefferies London Healthcare Conference on the same day at 11:00 a.m. GMT. Live audio webcasts will be available on Third Harmonic's website, with replays accessible for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD) reported Q3 2024 financial results, highlighting its Phase 1 SAD/MAD clinical trial of THB335 progressing towards data readout in Q1 2025. The company maintains a strong financial position with $296.1 million in cash and equivalents. Q3 2024 saw increased R&D expenses of $11.3 million, up from $6.0 million in Q3 2023, while net loss widened to $13.8 million from $7.3 million year-over-year. The company expects current cash reserves to fund operations through at least 2026.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2024. CEO Natalie Holles will engage in fireside chats at the following events:
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
- TD Cowen Virtual Chronic Urticaria Summit on September 20, 2024, at 3:00 p.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these sessions on its website. Archived replays will be available for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. CEO Natalie Holles will engage in fireside chats at the following events:
- Morgan Stanley 22nd Healthcare Conference on September 4, 2024, at 9:15 a.m. ET
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these presentations. These webcasts will be accessible through the Investors & Media section of Third Harmonic Bio's website, with archived replays available for 90 days after each event.
Third Harmonic Bio (Nasdaq: THRD) announced its Q2 2024 financial results and provided a business update. The company's Phase 1 SAD/MAD clinical trial for THB335 is progressing well, with results now expected in Q1 2025. Third Harmonic Bio reported a strong financial position with $255.3 million in cash and cash equivalents as of June 30, 2024, which is expected to fund operations through at least 2026.
Key financial highlights include:
- R&D expenses increased to $8.4 million for Q2 2024, up from $5.3 million in Q2 2023
- G&A expenses rose slightly to $5.7 million in Q2 2024 from $5.4 million in Q2 2023
- Net loss for Q2 2024 increased to $10.7 million, compared to $7.6 million in Q2 2023
The company is preparing to advance THB335 into a Phase 2 clinical trial for chronic spontaneous urticaria, with plans to expand into additional mast cell-mediated diseases.
FAQ
What is the current stock price of Third Harmonic Bio (THRD)?
What is the market cap of Third Harmonic Bio (THRD)?
